Ovid Therapeutics (OVID) Price to Earnings (2017 - 2026)

Ovid Therapeutics (OVID) has reported Price to Earnings for 10 consecutive years, with 33.11 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 560.96% year-over-year to 33.11; the trailing twelve-month figure through Jun 2026 stood at 14.41 (down 2244.25% YoY), and the FY2025 full-year result was 6.9, down 176.26% from the prior year.
• Price to Earnings slipped to 33.11 in Q2 2026 per OVID's latest filing, from 17.79 in the prior quarter.
• Across five years, Price to Earnings topped out at 12.44 in Q4 2025 and bottomed at 33.11 in Q2 2026.
• Historically, Price to Earnings has averaged 10.89 across 5 years, with a median of 11.11 in 2022.
• The sharpest annual moves came in 2022 and 2025: Price to Earnings sank 986.58% in 2022, then surged 274.28% in 2025.
• Over 5 years, Price to Earnings stood at 11.39 in 2022, then plunged by 30.4% to 14.86 in 2023, then soared by 51.96% to 7.14 in 2024, then soared by 274.28% to 12.44 in 2025, then slumped by 366.22% to 33.11 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 33.11, 17.79, and 12.44 for Q2 2026, Q1 2026, and Q4 2025 respectively.